Similarly, Hangxin Technology, a semiconductor company specializing in the design and manufacturing of high-performance chips, has also caught the eye of big funds looking to capitalize on the growing demand for semiconductor products. With a strong track record of delivering quality products and a solid growth strategy, Hangxin Technology has established itself as a key player in the semiconductor market. Investors are confident in the company's ability to navigate the competitive landscape and maintain its position as a market leader, which has led to significant investments from large funds.Proposal would end daylight saving timeAs the release date for "28 Years Later" approaches, anticipation is reaching fever pitch among fans who are eager to immerse themselves in the gripping world of the franchise once again. With its groundbreaking storytelling, compelling characters, and unrelenting tension, the sequel is poised to solidify its place as a modern classic in the pantheon of horror cinema.casino game 100 bonus 。

HUNTSVILLE, Texas (AP) — Jonah Pierce had 20 points in Presbyterian's 67-42 win against Youngstown State on Friday night. Pierce added nine rebounds for the Blue Hose (4-3). Kory Mincy scored 12 points, shooting 5 for 11, including 2 for 5 from beyond the arc. Kobe Stewart had 11 points and finished 4 of 9 from the field. The Penguins (2-3) were led by Ty Harper, who posted 12 points. EJ Farmer added 10 points and three steals for Youngstown State. Nico Galette also had five points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .The discovery of these ancient wooden tablets underscores the historical ties and cultural exchange between Korea and China. The presence of Chinese characters on the tablets suggests a deep connection between the two nations, highlighting the influence of Chinese writing and language on Korean society during ancient times. This cultural exchange played a crucial role in shaping the linguistic and literary landscape of Korea and contributed to the rich tapestry of Korean history.

High school recruiting isn't the only way to build a winner in the transfer portal eraRefund Brother's humility and positivity serve as a refreshing reminder that one's personal struggles do not define the entire landscape of an industry. His willingness to acknowledge his limitations while also celebrating the successes he achieved highlights a maturity that is often overlooked in today's fast-paced, hypercompetitive online world.

Swiss National Bank reduced its position in shares of Mr. Cooper Group Inc. ( NASDAQ:COOP – Free Report ) by 0.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 126,400 shares of the company’s stock after selling 700 shares during the period. Swiss National Bank’s holdings in Mr. Cooper Group were worth $11,652,000 as of its most recent filing with the Securities & Exchange Commission. A number of other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Mr. Cooper Group by 984.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 390,957 shares of the company’s stock worth $30,476,000 after buying an additional 354,905 shares in the last quarter. 1832 Asset Management L.P. purchased a new position in Mr. Cooper Group in the first quarter worth $5,301,000. Los Angeles Capital Management LLC lifted its holdings in Mr. Cooper Group by 50.7% in the third quarter. Los Angeles Capital Management LLC now owns 32,592 shares of the company’s stock valued at $3,004,000 after acquiring an additional 10,964 shares during the period. Waterfall Asset Management LLC purchased a new stake in shares of Mr. Cooper Group during the 2nd quarter worth $809,000. Finally, Advisors Asset Management Inc. acquired a new position in shares of Mr. Cooper Group during the 1st quarter worth $476,000. Institutional investors and hedge funds own 89.82% of the company’s stock. Insider Activity at Mr. Cooper Group In other news, CEO Jesse K. Bray sold 30,000 shares of Mr. Cooper Group stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $88.41, for a total transaction of $2,652,300.00. Following the completion of the sale, the chief executive officer now directly owns 818,821 shares in the company, valued at $72,391,964.61. The trade was a 3.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website . 2.33% of the stock is currently owned by corporate insiders. Wall Street Analyst Weigh In View Our Latest Report on Mr. Cooper Group Mr. Cooper Group Stock Performance COOP stock opened at $99.42 on Friday. The stock’s 50 day moving average price is $93.73 and its 200 day moving average price is $88.47. The firm has a market cap of $6.36 billion, a P/E ratio of 12.84 and a beta of 1.40. Mr. Cooper Group Inc. has a 1 year low of $59.03 and a 1 year high of $103.05. Mr. Cooper Group ( NASDAQ:COOP – Get Free Report ) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.30. The business had revenue of $616.00 million for the quarter, compared to the consensus estimate of $548.09 million. Mr. Cooper Group had a return on equity of 13.77% and a net margin of 25.87%. The business’s revenue was up 32.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.79 earnings per share. On average, research analysts predict that Mr. Cooper Group Inc. will post 10.16 earnings per share for the current year. Mr. Cooper Group Profile ( Free Report ) Mr. Cooper Group Inc, together with its subsidiaries, operates as a non-bank servicer of residential mortgage loans in the United States. The company operates through Servicing and Originations segments. The Servicing segment performs activities on behalf of investors or owners of the underlying mortgages and mortgage servicing rights, including collecting and disbursing borrower payments, investor reporting, customer service, modifying loans, performing collections, foreclosures, and the sale of real estate owned. Read More Want to see what other hedge funds are holding COOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mr. Cooper Group Inc. ( NASDAQ:COOP – Free Report ). Receive News & Ratings for Mr. Cooper Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mr. Cooper Group and related companies with MarketBeat.com's FREE daily email newsletter .In recent years, the upcoming action-adventure game "Black Myth: Wukong" has captured the attention of gamers and enthusiasts worldwide with its stunning visuals, fluid combat mechanics, and immersive storytelling. The game is inspired by the classic Chinese novel "Journey to the West," featuring the beloved character Wukong, also known as the Monkey King.

Robert F. Kennedy Jr.'s defection to Donald Trump and the Republicans comes after years of criticism the former Democrat laid at Trump's feet. Kennedy, whom Trump has nominated to be the next U.S. health secretary, has previously called the president-elect a "bully" and a "terrible president" and described his early political rise as "scary." In a video that was widely shared online this week, amid widespread discussion of Trump's cabinet picks, commentators claimed that Kennedy had disparaged Trump's supporters too, saying he called them "belligerent idiots," "outright Nazis," and "bootlickers." The Claim A post on X, formerly Twitter , by user Republicans against Trump, posted on November 21, 2024, viewed 3.9 million times, said: "[siren emoji] CNN has uncovered an audio in which RFK Jr scorched Trump and his supporters, calling them "belligerent idiots," "outright Nazis," "cowards," and "bootlickers." The post included audio in which Kennedy said: "One of the things that you write so beautifully, and your stuff is so fun to read, but you write about Trump, quote, 'The way that you build a truly vicious nationalist movement is to wed a relatively small core of belligerent idiots to a much larger group of opportunists and spineless fellow travelers whose primary function is to turn a blind eye to things.'" The Facts CNN did not report that Kennedy said those words about Trump supporters himself, and Kennedy did not do so either. CNN reported earlier this week that the recording was taken from a March 2016 episode of the Ring of Fire radio show, during which Kennedy praisingly repeated the words of journalist Matt Taibbi. "'We may not have that many outright Nazis in America, but we have plenty of cowards and bootlickers, and once those fleshy dominoes start tumbling into the Trump camp, the game is up,'" Kennedy quoted. As was said in the clip, Kennedy doesn't resist or challenge Taibbi's words, calling them "beautifully" written and "fun to read." The passage itself doesn't outright call Trump supporters "belligerent idiots" but strongly connects them to that insult. Importantly, these weren't Kennedy's words, although his praise of the passage suggests he, at the very least, sympathized with its sentiment. "Like many Americans, I allowed myself to believe the mainstream media's distorted, dystopian portrait of President Trump," Kennedy said in a statement sent to Newsweek by the Trump-Vance transition team. "I no longer hold this belief and now regret having made those statements. President Trump has a tremendous vision for our country that will not only make our country healthy again but will lower the cost of living for all Americans, stop endless wars, protect free speech, secure our Southern border, and make our country great again. "I am proud to serve in President Trump's administration." As reported in October 2024 by The New York Times, Kennedy has ridiculed Trump for many years, including during his run as a candidate in the 2024 race, calling him a "terrible president" who would not be "capable of meeting the expectations and fulfilling the promises that he raises with his rhetoric." In a Newsweek op-ed from 2018 , Kennedy, who was a Democrat at the time, said that Trump's "presidency has not just discredited our nation, but the entire American experiment in self government." Trump was not kind to Kennedy prior to his dropping out of the 2024 race, either. Kennedy ran against Trump as a Democrat, then an independent, before ending his campaign in August and endorsing the president-elect. In a post on his social media platform Truth Social in late May, Trump called Kennedy "one of the most Liberal Lunatics ever to run for office," adding that he is "a Phony Radical Left fool whose poll numbers are TERRIBLE, and getting worse." The Ruling Needs Context. According to a CNN report, the audio recording of RFK Jr. is from 2016 and was of Kennedy reading a passage written by journalist Matt Taibbi. While these weren't his words, Kennedy repeated them in praise. FACT CHECK BY Newsweek's Fact Check teamIn addition to the positive policy and earnings news, the A-share market has also been buoyed by the overall strength of the Chinese economy. Despite global economic challenges, China's economy has shown resilience and continued growth. The country's efforts to promote innovation, technological advancement, and economic restructuring have all played a role in sustaining economic growth and boosting investor confidence in the A-share market.

The naturalization process for foreign athletes seeking to represent China in international competitions is known to be rigorous and complex, requiring the submission of various documents and the fulfillment of specific criteria. In the case of Oscar, it has been reported that his naturalization materials have met the necessary requirements and have been officially submitted for review by the relevant authorities.As the trial progresses, new details emerge that shed light on the intricacies of the case. Witnesses are called to testify, evidence is presented, and arguments are fiercely debated. The courtroom becomes a battleground of words and emotions, with each side fighting tooth and nail for their version of the truth.

Trump asks Supreme Court to delay TikTok ban so he can weigh in after he takes officeClinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") CTXR , a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding Basic and diluted 6,726,999 6,051,789 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (39,425,839) $ (32,542,912) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 11,839,678 6,616,705 Issuance of common stock for services 284,176 102,000 Amortization of operating lease right-of-use asset 208,179 191,648 Depreciation 1,432 2,668 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (945,389) (5,036,926) Accounts payable 1,999,877 1,761,956 Accrued expenses (459,273) (929,094) Accrued compensation 72,035 394,732 Operating lease liability (218,380) (196,989) Net Cash Used In Operating Activities (28,201,375) (29,060,212) Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Proceeds from common stock option exercises - 31,267 Merger, net (3,831,357) Net proceeds from registered direct offerings 13,803,684 13,798,183 Net Cash Provided By Financing Activities 9,972,327 13,829,450 Net Change in Cash and Cash Equivalents (23,229,048) (15,230,762) Cash and Cash Equivalents – Beginning of Year 26,480,928 41,711,690 Cash and Cash Equivalents – End of Year $ 3,251,880 $ 26,480,928 Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $ - Prepaid Manufacturing transferred to Inventory $ 6,134,895 $ - Reflects a 1-for-25 reverse stock split effective November 25, 2024. View original content to download multimedia: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339718.html SOURCE Citius Pharmaceuticals, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.